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Etiopathogenesis of feline diabetes mellitus 
Prof. Dr. Claudia Reusch, Dipl ECVIM-CA 
Clinic for Small Animal Internal Medicine, University of Zurich, Switzerland 
 
The classification of diabetes mellitus in cats follows more or less the scheme used in human 
medicine. Although the etiopathogenic mechanisms may not be completely identical, the 
“human model” provides a guide for identification and differentiation of the various forms of 
the disease. 
Type 1 diabetes. This type accounts for 5 – 10% of human cases and was previously known 
as insulin-dependent diabetes (IDDM) or juvenile-onset diabetes. Although it is commonly 
seen in childhood and adolescence, it can occur at any age, even in the 8th or 9th decade of life. 
It most commonly (> 90%) results from cellular-mediated autoimmune destruction of the β-
cells leading to failure of insulin synthesis.  The characteristic pathological lesion in the 
pancreas is the presence of mononuclear immune cells around and within the islets. The 
destructive process is limited to the β-cells, all other endocrine cells of the islets are spared. A 
major marker of autoimmune type 1 diabetes is the presence of circulating autoantibodies 
against glutamic acid decarboxylase (GAD65), islet antigen-2 (IA-2),  insulin and  zink 
transporter 8 (ZnT8). This type of diabetes is associated with absolute insulin deficiency. In 
cats, type 1-like diabetes is generally considered to be rare. Lymphocytic infiltration into the 
islets (insulitis) as a marker of immune-mediated disease has only been described in a few 
cases.  Beta cell and insulin antibodies have so far not been demonstrated in newly diagnosed 
diabetic cats. 
Type 2 diabetes. It is currently assumed that approximately 80% of diabetic cats suffer from 
a type 2-like diabetes mellitus. Similar to human type 2 diabetes mellitus, feline type 2 
diabetes is a heterogeneous disease attributable to a combination of impaired insulin action in 
liver, muscle and adipose tissue (insulin resistance) and β-cell failure. Environmental as well 
as genetic factors are thought to play a role in the development of both defects.  
Genetic factors have just started to be investigated. Most likely, similar to humans, diabetes in 
the cat is a polygenic disease and many genes will be associated with an increased risk for the 
disease. The most convincing evidence of a genetic basis comes from studies in the Burmese 
cat. In breeding lines from Australia, New Zealand and the UK, the frequency of diabetes 
mellitus is reported to be about 4 times higher in Burmese cats than in domestic cats.  
 One of the major risk factors for the development of diabetes in cats is obesity. Others are 
male gender, physical inactivity and indoor confinement, increasing age and the 
administration of glucocorticoids and progestagens. It has been shown that obese cats are 
several  times more likely to develop diabetes mellitus compared to cats with an optimal 
weight. Also similar to humans, it is now recognized in cats that adipose tissue is an active 
and complex endocrine organ. It is important to note that although obesity induces insulin 
resistance, not all obese cats develop diabetes mellitus. Healthy β-cells adapt to obesity and 
insulin resistance by increasing insulin secretion to maintain normal glucose tolerance. For 
diabetes to develop, there must be β-cell dysfunction leading to impaired glucose tolerance 
and eventually type 2 diabetes. Unfortunately, there are nearly no data on β-cell function and 
insulin secretion in cats during the natural development of diabetes and the big question, what 
exactly leads to β-cell failure under natural conditions, is unanswered until today. One long-
known hypothesis concerns β-cell destruction by amyloid deposition. Only cats, humans and 
nonhuman primates have an amyloidogenic amino acid structure of IAPP with the potential to 
form amyloid depositions within the islets of the pancreas. Amyloid depositions have been 
found in many cats with diabetes, it is, however, also a frequent finding in non-diabetic cats. 
 Other specific types of diabetes (secondary diabetes mellitus). Diabetes in cats may develop 
as a consequence of another disease or the administration of diabetogenic drugs, such as 
glucocorticoids and progestins. These diseases may account for approximately up to 20% of 
diabetic cases in cats. Diabetes induced by glucocorticoids or progestins is relatively 
common. Pancreatitis has gained a lot of attention during the last years and it is now known 
that it is a relatively common disease in cats. The cause and effect of pancreatitis and diabetes 
in cats, however, is difficult to define and is largely unknown. Pancreatitis, however, seems to 
be a frequent co-morbidity and it is very likely that pancreatitis emerges during the course of 
the diabetic disease. In a substantial percentage of cats, it seems to be a clinical insignificant 
bystander, in others, it causes clinical signs and may render diabetic regulation at times very 
difficult.  Pancreatitis may also play a role in the development of diabetic ketoacidosis. In 
contrast, hypersomatotropism (acromegaly) and hyperadrenocorticism may cause diabetes 
mellitus. Nearly all cats with hypersomatotropism and approximately 80% of cats with 
hyperadrenocorticism will develop diabetes which often times is difficult to regulate due to 
severe insulin resistance. Whereas hyperadrenocorticism is a rare disorder, 
hypersomatotropism may be present in 10 – 15% of diabetic cats. Hyperthyroidism and 
hyperaldosteronism are rarely associated with overt diabetes and pheochromocytoma is 
extremely uncommon.  
 
 
 
REMISSION OF DIABETES IN CATS 
Remission of diabetes is defined as a situation in which clinical signs disappear, blood 
glucose concentration normalizes and insulin treatment (or other antidiabetic drugs) can be 
discontinued. Those cats most likely have a type 2-like diabetes resulting from insulin 
resistance and β-cell dysfunction and some degree of β-cell loss. Their remaining β-cells, 
however, have the capacity to recover, at least in part, during treatment. One of the major 
mechanism behind this phenomenon most likely is the abolishment of the damaging effects of 
high blood glucose on β-cells (glucotoxicity). Cats which do not experience diabetic 
remission may be in a more advanced stage of their disease with more pronounced β-cell loss 
and/or a more pronounced functional defect. Diabetic remission most often occurs during the 
first three to four months of therapy, however, remission one year and longer after start of 
therapy may occasionally be seen. Published remission rates vary widely. In our institution, 
remission rate is between 40 – 50% provided that the cats are newly diagnosed diabetics and 
do not suffer from any relevant concurrent disease.  
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